文献速递流行病学与生物统计临床试验与 GCP

评估两个亚组二分类终点的试验一致性:逻辑回归模型中的新检验

Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model.
PubMed 文献 · Stat Med · 2020-10-26

在后期药物开发中,需评估两个亚组二分类终点治疗效应的一致性。传统交互检验只能拒绝等效原假设而无法确认一致性,且把握度低、易过敏感。本文提出基于区间包含原则的一致性检验,可拒绝异质性并确认亚组效应一致性,同时控制I型错误,并在模拟研究中评估其性能。

要点

  • 交互检验无法确认一致性,且把握度低、对样本量敏感。
  • 新的一致性检验基于区间包含原则,可确认亚组效应一致性并控制I型错误。
  • 模拟显示新检验在真实小交互场景下把握度足够,但亚组不平衡、样本量低或界值窄时把握度下降。

核心结论

  • 基于区间包含原则的一致性检验可拒绝异质性并确认亚组特异性治疗效应的一致性,同时控制I型错误。

研究设计与样本

  • 方法学文章,提出基于逻辑回归模型的一致性检验,并通过模拟研究评估其性能。

主要发现

  • 交互检验只能拒绝等效原假设,不能确认一致性,且把握度低、可能因样本量而过度敏感。
  • 所提出的同质性检验基于总体治疗效应与亚组特异性效应在比值比尺度上的偏差,并与基于两亚组效应比值的等效性检验比较。
  • 模拟显示该同质性检验在真实小交互场景下达到足够把握度;亚组不平衡、样本量较低和界值较窄时把握度下降。
  • 严重交互作用被原假设覆盖,且交互越强越可能被拒绝。

临床怎么用

  • 在二分类终点的亚组一致性分析中,可考虑使用基于区间包含原则的一致性检验替代传统交互检验。

局限性

  • 研究基于模拟,未报告实际数据应用结果;亚组不平衡、样本量低和界值窄时把握度下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In late stage drug development, the experimental drug is tested in a diverse study population within the relevant indication. In order to receive marketing authorization, robust evidence for the therapeutic efficacy is crucial requiring investigation of treatment effects in well-defined subgroups. Conventionally, consistency analyses in subgroups have been performed by means of interaction tests. However, the interaction test can only reject the null hypothesis of equivalence and not confirm consistency. Simulation studies suggest that the interaction test has low power but can also be oversensitive depending on sample size-leading in combination with the actually ill-posed null hypothesis to findings regardless of clinical relevance. In order to overcome these disadvantages in the setup of binary endpoints, we propose to use a consistency test based on the interval inclusion principle, which is able to reject heterogeneity and confirm consistency of subgroup-specific treatment effects while controlling the type I error. This homogeneity test is based upon the deviation between overall treatment effect and subgroup-specific effects on the odds ratio scale and is compared with an equivalence test based on the ratio of both subgroup-specific effects. Performance of these consistency tests is assessed in a simulation study. In addition, the consistency tests are outlined for the relative risk regression. The proposed homogeneity test reaches sufficient power in realistic scenarios with small interactions. As expected, power decreases for unbalanced subgroups, lower sample sizes, and narrower margins. Severe interactions are covered by the null hypothesis and are more likely to be rejected the stronger they are.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Grill S, Ring A, Brannath W, et al. Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model. Stat Med. 2020. PMID: 33105519. doi:10.1002/sim.8719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。